Clinuvel Pharmaceuticals Ltd - Company Profile
Powered by 
All the data and insights you need on Clinuvel Pharmaceuticals Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Clinuvel Pharmaceuticals Ltd Strategy Report
- Understand Clinuvel Pharmaceuticals Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Clinuvel Pharmaceuticals Ltd (Clinuvel Pharmaceuticals) carries out the development of photo-protective drugs as a preventive treatment for light-related skin disorders. Clinuvel’s lead compound Scenesse (afamelanotide), is a first-in-class drug candidate which is photo protective drug against damage to the skin by UV radiation and sunlight.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s research and development (R&D) focuses on developing treatments for genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population and commercializing its lead drug candidate Scenesse. Clinuvel has conducted over 15 trials of Scenesse (afamelanotide 16mg) involving over 900 patients. It conducts R&D activities through its subsidiary Vallaurix Pte Ltd at the research & development center in Singapore. The company invested AUD1.27 million in R&D activities in FY2022.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer